Publication | Closed Access

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

Tumor BiologySurgical OncologyMalignant DiseaseMedicineStandard ChemotherapyMetronomic TherapyPathologyHistotype-tailored Neoadjuvant ChemotherapyCancer TreatmentOncologyRadiation OncologyCancer ResearchPhase 3